Zentalis Pharmaceuticals (NASDAQ:ZNTL) Announces Quarterly Earnings Results

Zentalis Pharmaceuticals (NASDAQ:ZNTL) issued its quarterly earnings results on Monday. The company reported ($0.34) EPS for the quarter, beating analysts’ consensus estimates of ($0.54) by $0.20, FiscalAI reports.

Zentalis Pharmaceuticals Price Performance

Shares of NASDAQ ZNTL opened at $1.80 on Wednesday. The stock has a market cap of $129.01 million, a PE ratio of -0.94 and a beta of 1.91. Zentalis Pharmaceuticals has a 1 year low of $1.25 and a 1 year high of $6.95. The firm has a fifty day moving average price of $2.66 and a 200-day moving average price of $3.40.

Insider Buying and Selling at Zentalis Pharmaceuticals

In related news, major shareholder Group Walters acquired 4,335,000 shares of the stock in a transaction dated Friday, August 14th. The stock was acquired at an average cost of $3.50 per share, with a total value of $15,172,500.00. Following the purchase, the insider directly owned 17,844,973 shares of the company’s stock, valued at approximately $62,457,405.50. This trade represents a 32.09% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Company insiders own 3.80% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts recently issued reports on the company. William Blair assumed coverage on Zentalis Pharmaceuticals in a report on Wednesday, September 16th. They set an “outperform” rating on the stock. Wells Fargo & Company started coverage on Zentalis Pharmaceuticals in a report on Wednesday, September 30th. They issued an “equal weight” rating and a $5.00 price objective for the company. HC Wainwright reiterated a “buy” rating and issued a $10.00 price objective on shares of Zentalis Pharmaceuticals in a research report on Monday, October 19th. Mizuho began coverage on Zentalis Pharmaceuticals in a research note on Friday, July 17th. They set an “outperform” rating and a $8.00 target price on the stock. Finally, Wall Street Zen downgraded Zentalis Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Saturday, August 8th. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $7.75.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) is a clinical-stage biopharmaceutical company focused on discovering and developing small-molecule medicines for the treatment of cancer. The company’s research is centered on therapies designed to target biological pathways involved in tumor growth, survival and resistance to existing treatments. Zentalis’ lead product candidate is azenosertib, formerly known as ZN-c3, an oral inhibitor of WEE1, a protein involved in regulating the cell cycle and DNA-damage response.